Skip to main content
. Author manuscript; available in PMC: 2015 Aug 15.
Published in final edited form as: Int J Cancer. 2014 Feb 4;135(4):939–947. doi: 10.1002/ijc.28732

Table 3.

Effect of starting age, ending age and PSA threshold, and frequency on cost-effectiveness

Screening strategy ICER ($/LYG)
Decreasing starting age
60(2)74 --
55(2)74 $27,600
50(2)74 $80,900
40(2)74 $494,000

Increasing ending age & threshold
50(2)69 --
50(2)74,4.0 dominated*
50(2)74 $48,100

Increasing frequency
50(4)74 --
50(A)74 $68,500
50(2)74 $1,150,000

Abbreviations: LYG, life-years gained; ICER, incremental cost-effectiveness ratio; see Table 2 for full screening strategy descriptions

*

Dominated strategies have a higher ICER (i.e., they are less cost-effective) than the next most effective strategy